News List

Evotec, Sanofi intend to create an Evotec-led Infectious Disease Open Innovation R&D Platform


The Evotec-led platform is open to academia, biotechnology and pharmaceutical companies, foundations, and government agencies

By Team ABLE

Germany’s Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.

In support of this platform, Sanofi will licence most of its infectious disease research and early-stage development portfolio and transfer its infectious disease research unit to Evotec. The transaction excludes the vaccine R&D unit and related projects. Evotec will combine its drug discovery and development expertise with these new assets and experts, committing to the expansion and acceleration of anti-infective drug discovery and development through open collaborations with other pharmaceutical and biotechnology companies, foundations, academia, and government agencies. More than 150 scientists within Evotec will be active in this field.

Sanofi will pay Evotec an initial one-time cash upfront payment of EUR 60 m and provide significant further long-term funding to ensure support and progression of the portfolio. Sanofi will retain certain option rights on the development, manufacturing, and commercialization of anti-infective products and will continue to be involved in infectious disease through its vaccines research and development and its global health programs.

Under the agreement, Evotec will integrate Sanofi\'s infectious disease research unit, which includes more than 100 employees into its global drug discovery and development operations. The transferred positions will be associated with specific commitments of employment for 5 years and will continue to be based near Lyon, taking advantage of the location\'s scientific and medical ecosystems.
Evotec will expand its existing long-term initiatives focused on innovation to fight infectious diseases including the maintenance of a portfolio of projects aimed at diseases affecting the developing world. The focus of drug discovery will at the outset be on new mode-of-action antimicrobials.

This transaction is expected to close in the first half of 2018, subject to finalization of definitive agreements and completion of the appropriate social process. This project will be conducted in full respect of social dialogue with employee\'s representatives.